Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute

This trial compared the efficacy and toxicity of standard first-line treatment with paclitaxel/carboplatin versus paclitaxel/carboplatin plus sorafenib in patients with advanced ovarian carcinoma. Patients with stage 3 or 4 epithelial ovarian cancer with residual measurable disease or elevated CA-12...

Descripción completa

Detalles Bibliográficos
Autores principales: Hainsworth, John D, Thompson, Dana S, Bismayer, John A, Gian, Victor G, Merritt, William M, Whorf, Robert C, Finney, Lindsey H, Dudley, B Stephens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430260/
https://www.ncbi.nlm.nih.gov/pubmed/25556916
http://dx.doi.org/10.1002/cam4.376

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430260/
https://www.ncbi.nlm.nih.gov/pubmed/25556916
http://dx.doi.org/10.1002/cam4.376

Ejemplares similares